Compare SAFE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | EVO |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1999 | N/A |
| Metric | SAFE | EVO |
|---|---|---|
| Price | $14.96 | $2.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $19.00 | $7.00 |
| AVG Volume (30 Days) | ★ 290.5K | 45.0K |
| Earning Date | 04-30-2026 | 04-08-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $4.31 | $10.05 |
| P/E Ratio | $37.75 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $2.31 |
| 52 Week High | $17.16 | $4.42 |
| Indicator | SAFE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 47.56 |
| Support Level | $14.70 | $2.88 |
| Resistance Level | $15.31 | $3.82 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 70.40 | 56.12 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.